APTENSIO XR CII
Generic Name and Formulations:
Methylphenidate HCl 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg; ext-rel caps.
Indications for APTENSIO XR:
Attention deficit hyperactivity disorder.
Adults and Children:
Individualize. Swallow whole or may open capsule and sprinkle contents onto applesauce. <6yrs: not established. ≥6yrs: 10mg once daily in the AM. May titrate dose in weekly increments of 10mg/day. Max 60mg/day. Discontinue if no improvement after dose adjustment over a 1-month period.
During or within 14 days of MAOIs.
Abuse potential (monitor). Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiating. Consider discontinuing if new psychotic/manic symptoms occur. Peripheral vasculopathy including Raynaud's phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR. Reduce dose or discontinue if paradoxical worsening of symptoms occurs. Write ℞ for smallest practical amount. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants.
See Contraindications. Hypertensive crisis with concomitant MAOIs. Risk of serotonin syndrome with serotonergic drugs.
Abdominal pain, decreased appetite, headache, insomnia; hypertension, tachycardia, priapism.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|